NEURALINK 2025: – Received FDA Breakthrough Device Designation for its speech restoration technology targeting severe speech impairments. – Launched its first clinical trial in the Middle East (UAE-PRIME) at Cleveland Clinic Abu Dhabi in partnership with the Department of